Nuformix plc Net Assets
Nuformix plc net assets. Based on the latest financial reports, Nuformix plc (NFX) has net assets worth GBX1.64 Million GBX (≈ $199.11 USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX1.86 Million ≈ $226.75 USD) and total liabilities (GBX227.21K ≈ $27.64 USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset momentum of Nuformix plc to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX1.64 Million |
| % of Total Assets | 87.81% |
| Annual Growth Rate | 10.52% |
| 5-Year Change | -84.07% |
| 10-Year Change | N/A |
| Growth Volatility | 56.66 |
Net Assets of Nuformix plc (2014–2025)
Net assets of Nuformix plc from 2014 to 2025. This chart illustrates how Nuformix plc's net assets have evolved over time, based on quarterly financial data. See Nuformix plc net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Nuformix plc (2014–2025)
The table below shows the annual net assets of Nuformix plc from 2014 to 2025. For live market cap and overall valuation, see NFX market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-09-30 | GBX754.93K ≈ $91.85 |
+5.50% |
| 2024-09-30 | GBX715.57K ≈ $87.06 |
-82.94% |
| 2023-09-30 | GBX4.20 Million ≈ $510.41 |
-0.78% |
| 2023-03-31 | GBX4.23 Million ≈ $514.45 |
-10.76% |
| 2022-03-31 | GBX4.74 Million ≈ $576.47 |
-16.68% |
| 2021-03-31 | GBX5.69 Million ≈ $691.85 |
+19.90% |
| 2020-03-31 | GBX4.74 Million ≈ $577.03 |
+24.30% |
| 2019-03-31 | GBX3.82 Million ≈ $464.22 |
-15.09% |
| 2018-03-31 | GBX4.49 Million ≈ $546.69 |
+2601.86% |
| 2017-03-31 | GBX-179.59K ≈ $-21.85 |
-135.75% |
| 2016-03-31 | GBX502.34K ≈ $61.12 |
-23.29% |
| 2015-12-31 | GBX654.83K ≈ $79.67 |
+690.71% |
| 2015-07-31 | GBX-110.86K ≈ $-13.49 |
-144.88% |
| 2014-07-31 | GBX247.00K ≈ $30.05 |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Nuformix plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 709942600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Nuformix plc Net Assets Breakdown (September 2025)
Nuformix plc net assets breakdown by equity component as of September 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | GBX1.41 Million | 186.44% |
| Other Comprehensive Income | GBX28.51K | 3.78% |
| Other Components | GBX6.84 Million | 905.39% |
| Total Equity | GBX754.93K | 100.00% |
Nuformix plc Competitors by Market Cap
The table below lists competitors of Nuformix plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SpaceandPeople Plc
LSE:SAL
|
$34.00K |
|
CULLINAN METALS CORP.
F:7KO
|
$34.16K |
|
Empire Metals Limited
LSE:GEO
|
$35.07K |
|
Keras Resources PLC
LSE:KRS
|
$35.31K |
|
Union Jack Oil plc
LSE:UJO
|
$33.88K |
|
Gfinity PLC
LSE:GFIN
|
$33.51K |
|
KCR Residential Reit PLC
LSE:KCR
|
$33.46K |
|
Holdco Nuvo Group D.G Ltd
NASDAQ:NUVOQ
|
$33.26K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nuformix plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 715,571 to 754,934, a change of 39,363 (5.5%).
- Net loss of 652,586 reduced equity.
- New share issuances of 691,950 increased equity.
- Other comprehensive income decreased equity by 35,848.
- Other factors increased equity by 35,847.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX-652.59K | -86.44% |
| Share Issuances | GBX691.95K | +91.66% |
| Other Comprehensive Income | GBX-35.85K | -4.75% |
| Other Changes | GBX35.85K | +4.75% |
| Total Change | GBX- | 5.50% |
Book Value vs Market Value Analysis
This analysis compares Nuformix plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 235.42x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 12.80x to 235.42x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-03-31 | GBX0.01 | GBX0.11 | x |
| 2017-03-31 | GBX0.00 | GBX0.11 | x |
| 2018-03-31 | GBX0.01 | GBX0.11 | x |
| 2019-03-31 | GBX0.01 | GBX0.11 | x |
| 2020-03-31 | GBX0.01 | GBX0.11 | x |
| 2021-03-31 | GBX0.01 | GBX0.11 | x |
| 2022-03-31 | GBX0.01 | GBX0.11 | x |
| 2023-03-31 | GBX0.01 | GBX0.11 | x |
| 2023-09-30 | GBX0.01 | GBX0.11 | x |
| 2024-09-30 | GBX0.00 | GBX0.11 | x |
| 2025-09-30 | GBX0.00 | GBX0.11 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nuformix plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -86.44%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.35x
- Recent ROE (-86.44%) is below the historical average (-41.77%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 299.60% | 152.04% | 0.34x | 5.73x | GBX270.21K |
| 2015 | 0.00% | -117.33% | 0.62x | 0.00x | GBX-193.08K |
| 2016 | -69.76% | -57.68% | 1.12x | 1.08x | GBX-400.65K |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | GBX-667.10K |
| 2018 | -40.91% | -12255.09% | 0.00x | 1.12x | GBX-2.29 Million |
| 2019 | -43.54% | -272.33% | 0.13x | 1.21x | GBX-2.04 Million |
| 2020 | -15.95% | -141.38% | 0.10x | 1.08x | GBX-1.23 Million |
| 2021 | -22.04% | -641.01% | 0.03x | 1.06x | GBX-1.82 Million |
| 2022 | -23.41% | -2217.99% | 0.01x | 1.05x | GBX-1.58 Million |
| 2023 | -17.98% | 0.00% | 0.00x | 1.06x | GBX-1.18 Million |
| 2023 | -13.66% | 0.00% | 0.00x | 1.05x | GBX-992.48K |
| 2024 | -508.89% | 0.00% | 0.00x | 1.36x | GBX-3.71 Million |
| 2025 | -86.44% | 0.00% | 0.00x | 1.35x | GBX-728.08K |
Industry Comparison
This section compares Nuformix plc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $6,870,539
- Average return on equity (ROE) among peers: -130.41%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nuformix plc (NFX) | GBX1.64 Million | 299.60% | 0.14x | $33.98K |
| 4BASEBIO UK SOCIETAS (4BB) | $11.70 Million | -27.66% | 0.26x | $998.55K |
| Aptamer Group PLC (APTA) | $8.05 Million | -26.00% | 0.43x | $93.52K |
| Arecor Therapeutics PLC (AREC) | $9.53 Million | -89.79% | 0.61x | $379.00K |
| Avacta Group PLC (AVCT) | $4.87 Million | -30.16% | 0.06x | $3.13 Million |
| BSF Enterprise Plc (BSFA) | $3.58 Million | -25.96% | 0.13x | $14.84K |
| Bioventix (BVXP) | $12.52 Million | 57.53% | 0.06x | $1.30 Million |
| Cizzle Biotechnology Holdings PLC (CIZ) | $6.63K | -327.34% | 1.48x | $55.46K |
| CRISM Therapeutics Corporation (CRTX) | $16.52 Million | -10.98% | 0.02x | $84.30K |
| Fusion Antibodies PLC (FAB) | $323.00K | 0.00% | 1.18x | $82.97K |
| Faron Pharmaceuticals Oy (FARN) | $1.61 Million | -823.73% | 5.34x | $436.55K |
About Nuformix plc
Nuformix plc, together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. The company develops NXP001, which is in the Phase 1 stage for use in oncology supportive care; NXP002, which is in the pre-clinical stage for the treatment of idiopathic pulmonary fibrosis… Read more